Galectin Therapeutics Yönetim
Yönetim kriter kontrolleri 4/4
Galectin Therapeutics' CEO is Joel Lewis, appointed in Sep 2020, has a tenure of 4.17 years. total yearly compensation is $963.65K, comprised of 59.5% salary and 40.5% bonuses, including company stock and options. directly owns 1.44% of the company’s shares, worth $2.25M. The average tenure of the management team and the board of directors is 3 years and 8.5 years respectively.
Anahtar bilgiler
Joel Lewis
İcra Kurulu Başkanı
US$963.6k
Toplam tazminat
| CEO maaş yüzdesi | 59.5% |
| CEO görev süresi | 4.2yrs |
| CEO sahipliği | 1.4% |
| Yönetim ortalama görev süresi | 3yrs |
| Yönetim Kurulu ortalama görev süresi | 8.5yrs |
Son yönetim güncellemeleri
Recent updates
Galectin rises as FDA approves to begin human trial of combination immunotherapy in head and neck cancer
Oct 12Galectin Therapeutics GAAP EPS of -$0.16
Aug 15Galectin: Ability To Potentially Target Unmet Medical Need
Jul 11Galectin: Pursuing A Subset In The NASH Space
Jul 01Read This Before Buying Galectin Therapeutics, Inc. (NASDAQ:GALT) Shares
Feb 25
Is Galectin Therapeutics (NASDAQ:GALT) In A Good Position To Deliver On Growth Plans?
Jan 21How Much Of Galectin Therapeutics, Inc. (NASDAQ:GALT) Do Insiders Own?
Dec 09Galectin Therapeutics reports Q3 results
Nov 09CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$48m |
| Mar 31 2024 | n/a | n/a | -US$45m |
| Dec 31 2023 | US$964k | US$574k | -US$45m |
| Sep 30 2023 | n/a | n/a | -US$45m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$40m |
| Dec 31 2022 | US$974k | US$523k | -US$39m |
| Sep 30 2022 | n/a | n/a | -US$35m |
| Jun 30 2022 | n/a | n/a | -US$35m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$1m | US$500k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$31m |
| Jun 30 2021 | n/a | n/a | -US$29m |
| Mar 31 2021 | n/a | n/a | -US$26m |
| Dec 31 2020 | US$1m | US$165k | -US$24m |
| Sep 30 2020 | n/a | n/a | -US$21m |
| Jun 30 2020 | n/a | n/a | -US$18m |
| Mar 31 2020 | n/a | n/a | -US$15m |
| Dec 31 2019 | US$189k | n/a | -US$20m |
| Sep 30 2019 | n/a | n/a | -US$18m |
| Jun 30 2019 | n/a | n/a | -US$19m |
| Mar 31 2019 | n/a | n/a | -US$20m |
| Dec 31 2018 | US$55k | n/a | -US$15m |
| Sep 30 2018 | n/a | n/a | -US$14m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$17m |
| Dec 31 2017 | US$172k | n/a | -US$17m |
Tazminat ve Piyasa: Joel's total compensation ($USD963.65K) is below average for companies of similar size in the US market ($USD1.48M).
Tazminat ve Kazançlar: Joel's compensation has been consistent with company performance over the past year.
CEO
Joel Lewis (54 yo)
4.2yrs
Görev süresi
US$963,647
Tazminat
Mr. Joel Lewis serves as Chief Executive Officer and President at Galectin Therapeutics, Inc since September 2, 2020 and Director since December 14, 2017. He served as the Managing Director of Shareholder...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 4.2yrs | US$963.65k | 1.44% $ 2.2m | |
| CFO, Treasurer & Corporate Secretary | 11.3yrs | US$561.42k | 0.013% $ 20.5k | |
| General Counsel | no data | Veri yok | Veri yok | |
| Head of CMC & Pharmaceutical Development | 1.8yrs | Veri yok | Veri yok | |
| Chief Medical Officer | less than a year | Veri yok | Veri yok | |
| Executive Assistant & Officer Manager | no data | Veri yok | Veri yok |
3.0yrs
Ortalama Görev Süresi
Deneyimli Yönetim: GALT's management team is considered experienced (3 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 6.9yrs | US$963.65k | 1.44% $ 2.2m | |
| Independent Director | 15.8yrs | US$87.24k | 0.033% $ 51.5k | |
| Independent Director | 10.2yrs | US$81.74k | 0.13% $ 205.6k | |
| Independent Chairman | 6.9yrs | US$71.74k | 16.53% $ 25.7m | |
| Independent Director | 13.1yrs | US$75.24k | 0.022% $ 34.0k | |
| Co-founder & Member of the Scientific Board | no data | US$203.69k | Veri yok | |
| Director | 4.9yrs | US$71.74k | 0.014% $ 21.8k | |
| Member of the Scientific Board | no data | Veri yok | Veri yok | |
| Independent Vice Chairman of the Board | 13.5yrs | US$87.74k | 0.21% $ 332.1k | |
| Member of Clinical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Clinical Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 4.2yrs | US$86.74k | 0.055% $ 85.2k |
8.5yrs
Ortalama Görev Süresi
74yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: GALT's board of directors are considered experienced (8.5 years average tenure).